Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Obama Signs 21st Century Cures Act Into Law



The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

Share this!

December 15, 2016 | by Sarah Hand, M.Sc.

This week, President Barack Obama signed the 21st Century Cures Act – a bill that promises additional funding for cancer research and opioid addiction prevention – into law. The legislation will allocate $1.8 billion for a cancer research “moonshot” project, which has gained tremendous support from Vice President Joe Biden.

In all, the 21st Century Cures Act will provide $6.3 billion in additional funding towards multiple large-scale projects. Under the bill, states will be provided with $1 billion in funding over a two year period to use towards the prevention and treatment of opioids and other drug addictions.

The bill will also change the way the US Food and Drug Administration (FDA) approves new drugs, potentially allowing them to accept alternative data sources to expedite the approvals process. Patient advocacy groups like Public Citizen have been strongly opposed to this part of the act, arguing that it will weaken the drug approvals process.

“This bill remains a bad deal for patient safety, offering a small, temporary and non-guaranteed increase in public research funding at the expense of permanently weakening oversight by the Food and Drug Administration,” said a spokesperson from Public Citizen. The group is a non-profit organization that aims to represent all US citizens, and their interests, in Washington, D.C.

The signing event represented a rare moment of bipartisanship, with both parties offering their support for the bill. “I hope this bodes well for what will come next year - that we're back working together,” said Biden.

The 21st Century Cures Act was passed in the US House of Representatives earlier this month in a landslide 392 to 26 vote. As predicted, the bill easily passed through the Senate to allow it to be signed into law before the close of 2016.

Keywords: Cancer, FDA, Opioids


Share this with your colleagues!

German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News

Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News

Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


Top 5 Most Impactful Tweets in Drug Development During the Last Week


Serialized? Yes. But are Products Still Being Diverted?

Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors

Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model

Imaging-based Subtypes of Pancreatic Cancer

Copyright © 2016-2017 Honeycomb Worldwide Inc.